RECURRENT BURKITT LYMPHOMA
Clinical trials for RECURRENT BURKITT LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT BURKITT LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT BURKITT LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cocktail shows promise for Hard-to-Treat lymphoma
Disease control OngoingThis early-stage study is testing a combination of three drugs—obinutuzumab, venetoclax, and lenalidomide—in people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to treatment. The main goal is to find the safest dose and see how well the drugs work togethe…
Matched conditions: RECURRENT BURKITT LYMPHOMA
Phase: PHASE1 • Sponsor: Beth Christian • Aim: Disease control
Last updated May 17, 2026 08:50 UTC
-
New combo therapy aims to boost immune attack on tough lymphomas
Disease control OngoingThis phase 2 trial tests whether adding varlilumab to nivolumab helps people with aggressive B-cell lymphomas that have returned or not responded to standard therapy. About 54 participants will receive either nivolumab alone or nivolumab plus varlilumab. The goal is to see if the…
Matched conditions: RECURRENT BURKITT LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:40 UTC
-
Promising lymphoma combo study pulled before it even started
Disease control TerminatedThis study planned to test a combination of three drugs (rituximab, venetoclax, and bortezomib) in adults with a type of aggressive lymphoma that had come back or stopped responding to standard treatment. The goal was to see if the combination could shrink or control the cancer. …
Matched conditions: RECURRENT BURKITT LYMPHOMA
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated May 04, 2026 16:31 UTC
-
New combo therapy offers hope for Tough-to-Treat lymphomas
Disease control OngoingThis study tests a combination of two drugs, nivolumab and lenalidomide, in people with non-Hodgkin or Hodgkin lymphoma that has returned or no longer responds to standard treatments. The goal is to find the best dose and see how well the combination works at shrinking tumors. Ab…
Matched conditions: RECURRENT BURKITT LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC